Wachtel Heather, Cerullo Isadora, Bartlett Edmund K, Kelz Rachel R, Karakousis Giorgos C, Fraker Douglas L
Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA,
Ann Surg Oncol. 2015;22(6):1781-8. doi: 10.1245/s10434-014-4201-9. Epub 2014 Oct 30.
Parathyroidectomy remains the only definitive treatment for primary hyperparathyroidism. We studied our large series of parathyroidectomies to identify factors predictive of failure to meet intraoperative parathyroid hormone (IOPTH) monitoring criteria.
We performed a retrospective cohort review of patients who underwent initial parathyroidectomy for primary hyperparathyroidism with IOPTH monitoring. Primary outcome was intraoperative failure, defined as failure to decrease IOPTH by ≥50 % and into normal range. Univariate and multivariate analyses were performed to determine factors associated with intraoperative failure. A subset analysis evaluated 6-month outcomes.
Of 2,185 subjects, 5.0 % (n = 110) experienced intraoperative failure. The intraoperative failure group had more multigland disease (35.2 vs. 16.6 %, p < 0.001) and smaller glands (1.3 vs. 1.5 cm, p = 0.048) compared to patients who experienced intraoperative success. On multivariate analysis, PTH level was statistically, but not clinically, significantly associated with intraoperative failure (odds ratio 1.0, 95 % confidence interval 1.000-1.003). Persistent hyperparathyroidism was identified in 2.5 % (n = 15) of 592 patients with ≥6 month follow-up. Median IOPTH decrease was lower in patients with persistent hyperparathyroidism (67.1 vs. 85.8 %, p < 0.001). IOPTH criteria were 93.7 % sensitive and 40.0 % specific for eucalcemia 6 months postoperatively. Of 15 patients with persistent hyperparathyroidism, 7 underwent reoperation with a 100 % cure rate. Reoperative diagnoses included ectopic mediastinal glands (n = 3), hyperplasia (n = 3), and missed second adenoma (n = 1).
Intraoperative failure is associated with higher rates of multigland disease and smaller parathyroid glands. Patients with persistent disease had significantly lower decreases in IOPTH, but half of patients who experienced failure by IOPTH criteria were eucalcemic 6 months postoperatively. All patients undergoing reoperation experienced successful cure.
甲状旁腺切除术仍然是原发性甲状旁腺功能亢进的唯一确定性治疗方法。我们研究了我们大量的甲状旁腺切除术病例,以确定预测未能达到术中甲状旁腺激素(IOPTH)监测标准的因素。
我们对接受原发性甲状旁腺功能亢进初次甲状旁腺切除术并进行IOPTH监测的患者进行了回顾性队列研究。主要结局是术中失败,定义为IOPTH未能降低≥50%且未进入正常范围。进行单因素和多因素分析以确定与术中失败相关的因素。亚组分析评估了6个月的结局。
在2185名受试者中,5.0%(n = 110)经历了术中失败。与术中成功的患者相比,术中失败组有多腺体疾病的比例更高(35.2%对16.6%,p < 0.001)且腺体更小(1.3对1.5 cm,p = 0.048)。多因素分析显示,PTH水平与术中失败在统计学上有显著关联,但在临床上无显著意义(比值比1.0,95%置信区间1.000 - 1.003)。在592名随访≥6个月的患者中,2.5%(n = 15)被确定为持续性甲状旁腺功能亢进。持续性甲状旁腺功能亢进患者的术中IOPTH降低中位数更低(67.1%对85.8%,p < 0.001)。IOPTH标准对术后6个月血钙正常的敏感性为93.7%,特异性为40.0%。在15名持续性甲状旁腺功能亢进患者中,7名接受了再次手术,治愈率为100%。再次手术诊断包括异位纵隔腺体(n = 3)、增生(n = 3)和漏诊的第二个腺瘤(n = 1)。
术中失败与多腺体疾病发生率较高和甲状旁腺腺体较小有关。持续性疾病患者的IOPTH降低明显更低,但根据IOPTH标准失败的患者中有一半在术后6个月血钙正常。所有接受再次手术的患者均成功治愈。